Method and composition for treating osteoarthritis

ABSTRACT

A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis.

FIELD OF THE INVENTION

This invention relates to a method for treating osteoarthritis. In particular, the present invention is directed to a safe, non-toxic anti-inflammatory treatment for osteoarthritis. The present invention also relates to the anti-inflammatory agents for use in the method.

BACKGROUND OF THE INVENTION

Osteoarthritis (“OA”) is a prevalent, painful, but treatable inflammatory disease that affects millions of Americans. While current treatment modalities include weight reduction and various dietary supplements, such as glucosamine, chondroitin, and green lip mussel, OA is most commonly treated with a class of drugs known as non-steroidal anti-inflammatory drugs (“NSAIDs”), e.g., ibuprofen and Rimadyl. NSAIDs are generally effective but have a number of toxic side effects that compromise the gastrointestinal, renal, and/or cardiovascular health of many patients.

It is clinically known that NSAID side effects include stomach bleeding, heart risks, and liver and kidney toxicity. These side effects have been directly linked to inhibition of the cyclooxygenase (“COX”) enzyme, the anti-inflammatory mechanism of action for NSAIDs. Recently, there has also been research that shows current NSAID treatment increases oxidative stress which, in turn, initiates an overall degradation of a person's health and immune system and results in the slowed healing of bones, tendons, ligaments, and muscles. In addition, NSAIDs may become addictive.

The market has attempted to develop less toxic alternatives that are still effective at providing relief and pain management. However, attempts to date have been relatively unsuccessful. Compounds that were considered “safe” for use either did not prove to effectively reduce inflammation in cases like OA or expressed unexpected toxicity in certain situations or among certain groups of patients. Given the current therapeutic options available, there remains a need for additional treatments to effectively manage the pain and reduced mobility associated with OA without the toxic side effects provided by current over-the-counter and prescription

NSAIDs.

SUMMARY OF THE INVENTION

The present invention is directed to a method for treating an inflammatory disease, such as osteoarthritis, including administering an anti-inflammatory agent to a patient, wherein the patient may be a human or an animal, and wherein the animal may be a canine, wherein the anti-inflammatory agent includes ethyl (α-guanido-methyl) ethanoate. While the mechanism by which ethyl (α-guanido-methyl) ethanoate acts at the cellular level is likely to involve multiple anti-inflammatory pathways, they are unique from NSAIDs and other dietary supplements in current use for treating OA. In one embodiment, the anti-inflammatory agent is administered to the patient in an oral dosage or as a topical application. The topical application may be administered in an amount of about 0.5 mL to about 5 mL. The oral dosage may be administered in an amount of about 400 mg to about 2400 mg.

The present invention is also directed to a method for reducing acute blood levels of pro-inflammatory marker, serum amyloid A, including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. In one embodiment, the acute blood levels of serum amyloid A are reduced by about 30 percent to about 70 percent when compared to levels of serum amyloid A prior to administration of the anti-inflammatory agent. In this aspect of the invention, the anti-inflammatory agent may be administered to the patient in an oral dosage of about 400 mg to about 2400 mg.

In another aspect, the present invention is directed to a method for reducing production and release of pro-inflammatory prostanoids in cells including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. In one embodiment, the pro-inflammatory prostanoids are reduced by about 50 percent or more when compared to an amount of pro-inflammatory prostanoids prior to administration of the anti-inflammatory agent. In another embodiment, the pro-inflammatory prostanoids are reduced by about 70 percent or more when compared to an amount of pro-inflammatory prostanoids prior to administration of the anti-inflammatory agent. In this aspect, the pro-inflammatory prostanoids include prostaglandin E₂.

In yet another aspect, the present invention is directed to a method for reducing levels of serum amyloid A, pro-inflammatory prostanoids, and tumor necrosis factor alpha in a patient, including administering an effective amount of ethyl (α-guanido-methyl) ethanoate to the patient. In one embodiment, the levels of serum amyloid A are reduced by about 40 percent to about 60 percent when compared to levels of serum amyloid A prior to administration of the ethyl (α-guanido-methyl) ethanoate; the levels of pro-inflammatory prostanoids are reduced by about 50 percent or more when compared to levels of pro-inflammatory prostanoids prior to administration of the ethyl (α-guanido-methyl) ethanoate; and the levels of tumor necrosis factor alpha are reduced by about 40 percent to about 60 percent when compared to levels of tumor necrosis factor alpha prior to administration of the ethyl (α-guanido-methyl) ethanoate. In this aspect, the effective amount of ethyl (α-guanido-methyl) ethanoate is an oral dosage of about 400 mg to about 2400 mg. The ethyl (α-guanido-methyl) ethanoate may also be administered with at least one other compound including homeopathic compounds, co-medications, nutraceuticals, plant extracts, herbal preparations, and cosmetic agents.

BRIEF DESCRIPTION OF THE DRAWINGS

Further features and advantages of the invention can be ascertained from the following detailed description that is provided in connection with the drawings described below: FIG. 1 is a graph comparing the effects of ibuprofen and Alpha-GEE on the release of prostaglandin E₂ (“PGE₂”) in brain endothelial cells;

FIG. 2 is a graph comparing the effects of ibuprofen and Alpha-GEE on the inhibition of cyclooxygenase (“COX”) activity;

FIG. 3 is a graph comparing the effects of Alpha-GEE and other compounds on PGE₂ release in cultured canine chondrocytes; and

FIG. 4 is a graph comparing the effects of Alpha-GEE and other compounds on tumor necrosis factor alpha (“TNFa”) release in cultured canine chondrocytes.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a method for treating OA, the anti-inflammatory agents and compositions useful in the method, and kits for application of the method. In particular, the present invention provides a method for safe, non-toxic relief from the pain and inflammation caused by OA. In one embodiment, the method of the present invention includes administering an anti-inflammatory agent to a patient in order to reduce pain and increase lost mobility associated with OA.

The Compound

Arthritis, such as OA, is an inflammatory condition within the joint that occurs through activation and interaction of multiple inflammatory cascades. Without being bound by any particular theory, the common pathways for inflammatory conditions are believed to include: 1) infiltration of immune macrophage cells into the joint and activation of toll receptors on immune cells and chondrocyte cells within the joint; 2) release of multiple proinflammatory cytokines from chondrocytes within the joint; 3) production and release of inflammatory arachidonic acid metabolites (prostaglandins); and 4) mitochondrial dysfunction. Current anti-inflammatory treatments, including conventional NSAIDs, are directed at preventing arachidonic acid metabolites (e.g., prostaglandins) from being produced and released. These treatments involve the suppression or inhibition of the cyclooxygenase enzymes. While such treatments can reduce the pain caused by osteoarthritis, it represents a rather late stage component of the inflammatory process. Thus, conventional NSAIDs treat the pain produced by inflammation within the arthritic joint, but have minimal impact on the inflammation present.

In contrast, the compound of the present invention is an anti-inflammatory agent that is unique in that it works in a pro-inflammatory manner. Unlike conventional NSAIDs, the compound of the present invention prevents prostaglandin production and release without direct inhibition of cyclooxygenase enzymes. In other words, rather than masking pain by blocking sensory perception/neuro-communicative pathways, the anti-inflammatory agent for use in the method of the present invention attacks the “origin” of inflammation, i.e., mitochondrial dysfunction. In particular, the anti-inflammatory agent of the present invention stabilizes the mitochondrial transition permeability, which is important to the ionic gradient and health of the mitochondria, and thus prevents leakage of various proteins that then induce a cytokine response which starts the chemical cascade that is consistent with the inflammatory model.

In one embodiment, the anti-inflammatory agent may include ethyl (α-guanido-methyl) ethanoate (“Alpha-GEE”). Data indicates that Alpha-GEE has a positive effect on toll receptors. Toll receptors act as a key part of our body's recognition mechanism and appear to be a major factor in the onset and/or progression of various medical indications including those that involve inflammation and pain. In particular, real time PCR or immunofluorescent staining of exposed cells was used to assess expression of toll-like receptor-2 (TLR-2), TLR-3, TLR-4, and TLR-7. Alpha-GEE appears to possess immunostimulatory properties and increases expression of TLR-2, TLR-3, TLR-4, and TLR-7 in cells. Without being bound by any particular theory, the mechanism by which TLR expression seems to be altered involves decreased pro-inflammatory mediator production in the wake of exposure to Alpha-GEE.

Alpha-GEE may be produced via acid-catalyzed conjugation of three amino acids. Once conjugated, the amino acids demonstrate anti-inflammatory properties comparable, if not superior, to conventional NSAIDs. For example, the anti-inflammatory agent, Alpha-GEE, has been found to reduce numerous inflammatory markers in the body including prostaglandin E₂ (“PGE₂”) plasma levels, serum amyloid A (“SAA”) levels, and tumor necrosis factor alpha (“TNFa”) levels.

In one embodiment, the anti-inflammatory agent of the present invention has been found to reduce production and release of pro-inflammatory prostanoids in cells. Pro-inflammatory prostanoids are mediators in inflammatory reactions and include prostaglandin E₂ (“PGE₂”). The anti-inflammatory agent of the present invention has been found to reduce PGE₂ levels by about 50 percent or more with Alpha-GEE concentrations of about 20 μM or more. In one embodiment, the reduction of PGE₂ levels is about 55 percent or more at an Alpha-GEE concentration level of about 20 μM or more. In another embodiment, the effects of Alpha-GEE at a concentration of about 20 μM or more result in a reduction of PGE₂ release of about 60 percent or more. In yet another embodiment, the effects of Alpha-GEE at a concentration of about 20 μM or more result in a reduction of PGE₂ release of about 70 percent or more. For example, a concentration of about 20 μM or more of Alpha-GEE may result in a reduction of PGE₂ release in brain endothelial cells of at least 50 percent or more, preferably about 55 percent or more, more preferably about 60 percent or more, and even more preferably about 70 percent or more.

When the concentration of Alpha-GEE is about 100 μM or more, the reduction of PGE₂ levels is about 55 percent or more. In another embodiment, the effects of Alpha-GEE at a concentration of about 100 μM or more result in a reduction of PGE₂ release of about 60 percent or more. In yet another embodiment, the effects of Alpha-GEE at a concentration of about 100 μM or more result in a reduction of PGE₂ release of about 70 percent or more. For example, a concentration of about 100 μM or more of Alpha-GEE may result in a reduction of PGE₂ release in brain endothelial cells of at least 50 percent or more, preferably about 55 percent or more, more preferably about 60 percent or more, and even more preferably about 70 percent or more.

Administration of Alpha-GEE at concentrations of about 100 μM results in about 50 percent reduction in PGE₂ release after about four hours. In one embodiment, at least about a 60 percent reduction in PGE₂ release is observed after about a four hour treatment with Alpha-GEE. For example, a concentration of about 100 μM of Alpha-GEE may result in a reduction of PGE₂ release in canine chondrocytes of about 50 percent, preferably about 60 percent, after about a four hour treatment.

In another embodiment, at least about a 60 percent reduction in PGE₂ release is observed after about an eight hour treatment with Alpha-GEE. In yet another embodiment, at least about a 70 percent reduction in PGE₂ release is observed after about an eight hour treatment of the with Alpha-GEE. In still another embodiment, administration of Alpha-GEE results in at least about a 75 percent reduction in PGE₂ release after about eight hours. In particular, administration of Alpha-GEE may result in a reduction of PGE₂ release in canine chondrocytes of at least about 60 percent, preferably at least about 70 percent, and more preferably at least about 75 percent, after about an eight hour treatment

In this aspect of the invention, comparing the reduction of PGE₂ release over a four to eight hour time period when treated with Alpha-GEE, NSAID (Rimadyl), glucosamine, or a TNFa receptor, Alpha-GEE has the most rapid effect on the reduction of PGE₂ release. Accordingly, in one embodiment, Alpha-GEE has at least about a 10 percent greater reduction in PGE₂ release after about four hours as compared to NSAID (Rimadyl), glucosamine, and a TNFa receptor blocker (inhibitor). In another embodiment, Alpha-GEE has at least about a 20 percent greater reduction in PGE₂ release after about four hours as compared to NSAID (Rimadyl), glucosamine, and a TNFa receptor blocker. In another embodiment, Alpha-GEE has at least about a 25 percent greater reduction in PGE₂ release after about four hours as compared to NSAID (Rimadyl), glucosamine, and a TNFa receptor blocker. For example, Alpha-GEE has at least about a 10 percent greater, preferably about 20 percent greater, more preferably about 25 percent greater, reduction in PGE₂ release in canine chondrocytes after about four hours as compared to NSAID (Rimadyl), glucosamine, and a TNFa receptor blocker (inhibitor).

The release of PGE₂ is reduced by at least about 10 percent from the fourth hour post-administration with Alpha-GEE to the eighth-hour post-treatment with Alpha-GEE. In one embodiment, PGE₂ release is reduced by at least about 15 percent from hour 4 to hour 8 when Alpha-GEE is administered. For example, PGE₂ release in canine chondrocytes is reduced by at least about 10 percent, preferably at least about 15 percent, from hour 4 to hour 8 when Alpha-GEE is administered.

While the reduction in prostaglandin release observed with Alpha-GEE are somewhat similar in magnitude to that observed with NSAID treatment, the anti-inflammatory pathway for Alpha-GEE is believed to be different from that of NSAIDs commonly used to treat conditions such as OA. As such, in one embodiment, administration of Alpha-GEE over a concentration range of 0.1 to 100 μM shows little to no change in percent inhibition of cyclooxygenase (“COX”) activity. In one embodiment, administration of Alpha-GEE in an amount of 0.1 μM results in about 20 percent inhibition of cyclooxygenase-1 (“COX-1”) activity, while administration of Alpha-GEE in amounts of 1 μM, 10 μM, and 100 μM results in about 20 percent inhibition, about 15 percent inhibition, and about 15 percent inhibition of COX-1 activity, respectively. In another embodiment, administration of Alpha-GEE in an amount of 0.1 μM results in about 10 percent inhibition of cyclooxygenase-2 (“COX-2”) activity, while administration of Alpha-GEE in amounts of 1 10 and 100 μM results in about 15 percent inhibition, about 18 percent inhibition, and about 15 percent inhibition of COX-2 activity, respectively. Accordingly, as Alpha-GEE does not demonstrate a concentration dependency, there is no mechanistic inhibition of the COX enzymes.

In one embodiment, administration of Alpha-GEE at any concentration ranging from 0.1 μM to 100 μM results in less than about a 10 percent deviation in inhibition of the activity of COX-1, COX-2, or both. In another embodiment, administration of Alpha-GEE at any concentration ranging from 0.1 μM to 100 μM results in about a 5 percent or less deviation in inhibition of the activity of COX-1. In yet another embodiment, administration of Alpha-GEE at any concentration ranging from 0.1 μM to 100 μM results in about an 8 percent or less deviation in inhibition of the activity of COX-2.

In this aspect of the invention, the administration of Alpha-GEE results in less than about 10 percent inhibition of the activity of cyclooxygenase-1 (“COX-1”), cyclooxygenase-2 (“COX-2”), or both. In one embodiment, the activity of COX-1, COX-2, or both is inhibited by less than about 7 percent upon administration of Alpha-GEE. In another embodiment, the administration of Alpha-GEE results in less than about 5 percent inhibition of the activity of COX-1, COX-2, or both. In yet another embodiment, the administration of Alpha-GEE results in less than about 3 percent inhibition of the activity of COX-1, COX-2, or both. In still another embodiment, the administration of Alpha-GEE results in less than about 1 percent inhibition of the activity of COX-1, COX-2, or both.

In another embodiment, the anti-inflammatory agent of the present invention has been found to reduce acute blood levels of the pro-inflammatory marker, SAA. SAA proteins are expressed in response to inflammatory stimuli. Administration of the anti-inflammatory agent of the present invention results in the reduction of acute blood levels of SAA by at least about 30 percent to about 70 percent compared to values prior to treatment. In one embodiment, when Alpha-GEE is administered, the SAA levels are reduced by about 40 percent to about 60 percent compared to values prior to treatment. In particular, one embodiment contemplates a reduction of acute blood levels of SAA by about 30 percent to about 70 percent when canines receive a dose of at least about 36 mg/kg over a two-week period.

In yet another embodiment of the present invention, the anti-inflammatory agent has been found to reduce the release of TNFa. TNFa is a cytokine involved in systemic inflammation. TNFa produces much of the inflammation that leads to cartilage destruction in the joint, as well as contributing to PGE₂ production through COX-2 enzyme induction. The anti-inflammatory agent of the present invention has been found to reduce TNFa release by about 40 percent to about 60 percent after a time period of about 8 to about 48 hours post-treatment. In one embodiment, the reduction in TNFa release is about 45 percent to about 55 percent after a time period of about 8 to about 48 hours post-treatment. For example, administration of Alpha-GEE has been found to reduce TNFa release in canine chondrocytes by about 40 percent to about 60 percent, preferably by about 45 percent to about 55 percent, after a time period of about 8 to about 48 hours post-treatment.

In particular, the anti-inflammatory agent of the present invention has been found to reduce TNFa release by at least about 20 percent after a time period of about 8 to about 24 hours post-treatment. In one embodiment, the anti-inflammatory agent of the present invention has been found to reduce TNFa release by at least about 30 percent after a time period of about 8 to about 24 hours post-treatment. In another embodiment, the anti-inflammatory agent of the present invention has been found to reduce TNFa release by at least about 40 percent after a time period of about 8 to about 24 hours post-treatment. For example, administration of Alpha-GEE has been found to reduce TNFa release in canine chondrocytes by at least about 20 percent, preferably at least about 30 percent, and more preferably at least about 40 percent, after a time period of about 8 to about 24 hours post-treatment.

In still another embodiment, the reduction in TNFa release is at least about 50 percent after a time period of about 48 hours post-treatment. In yet another embodiment, the reduction in TNFa release is at least about 60 percent after a time period of about 48 hours post-treatment.

For example, administration of Alpha-GEE has been found to reduce TNFa release in canine chondrocytes by at least about 50 percent, preferably at least about 60 percent, after a time period of about 48 hours post-treatment.

Administration

The anti-inflammatory agent may be produced in powder or crystal form. In one embodiment, the anti-inflammatory agent is encapsulated or tableted for an oral dosage. For example, the anti-inflammatory agent may be administered in the form of a pill, tablet, capsule, or gel capsule. In another embodiment, the anti-inflammatory agent may be administered in a liquid form. For example, the anti-inflammatory agent may be administered as an elixir. In yet another embodiment, the anti-inflammatory agent may be blended into a cream for a topical application. The anti-inflammatory agent may also be encompassed in a gel or similar form for topical application.

In one embodiment, the anti-inflammatory agent is administered orally to a patient. A patient may include, but is not limited to, a human, a canine, and an animal. Oral dosages range from use “as needed” to daily dosages of 1-2 capsules taken 1-3 times daily depending on the severity of symptoms. In one embodiment, an effective oral dosage of the anti-inflammatory agent ranges from about 400 mg to 2400 mg per day, or about 5 mg/kg to about 30 mg/kg. In another embodiment, an effective oral dosage ranges from about 400 mg to about 800 mg, or about 5 mg/kg to about 10 mg/kg. In yet another embodiment, an effective oral dosage ranges from about 400 mg to about 1200 mg, or about 5 mg/kg to about 15 mg/kg.

The anti-inflammatory agent may also be administered to the site as a topical cream or gel. In one embodiment, an effective topical cream or gel dosage ranges from use “as needed” to 1 mL-10 mL applied 1-4 times daily while cleansing the area between uses to keep pores open. In another embodiment, an effective topical cream or gel dosage ranges from about 0.5 mL to about 5 mL applied 1-4 times daily.

The anti-inflammatory agent of the present invention may be blended with or administered in conjunction with at least one other compound. In one embodiment, the at least one other compound includes a homeopathic compound, a co-medication, a nutraceutical, a plant extract, a herbal preparation, a cosmetic agent, a pharmaceutical, or combinations thereof. In another embodiment, the anti-inflammatory agent is present in a composition or blend with at least two other compounds.

Suitable homeopathic compounds include, but are not limited to, actaea spicata, aesculus hippocastanum, arnica montana, belladonna, bellis perennis, bryonia, calcarea carbonica, calcarea fluorica, calc sulph MM, causticum, cayenne, cimicifuga racemosa, formicum acidum, hamamelis virginiana, hypericum perforatum, magnesia phosphorica, phytolacca decandra, pulsatilla, rhododendron chrysanthum, rhus toxicodendron, ruta graveolens, salicylicum acidum, sepia, sulphu, turmeric, green tea extract, grape extract, foeniculum vulgare, bellis perrinis, boswellia serrate, bromeliacaea, devil's claw (harpagophytum procumbens), bromelain, cordyalis yanhusuo, or combinations thereof.

Although the present invention has been described in teems of treating a patient having osteoarthritis, the present invention contemplates the use of the anti-inflammatory agent of the present invention to treat other inflammatory joint diseases. For example, the anti-inflammatory agent of the present invention may be used to treat different types of arthritis including rheumatoid arthritis.

EXAMPLES

The following non-limiting examples are merely illustrative of the preferred embodiments of the present invention, and are not to be construed as limiting the invention, the scope of which is defined by the appended claims.

Example 1 Double Blind Randomized Trial in OA Canines

The following example evaluates the effectiveness of Alpha-GEE on both pain and mobility in a double-blind randomized trial in canines having OA. Results of the study indicate that evaluation of pain and mobility during the course of the trial demonstrated a significant improvement in canines receiving Alpha-GEE compared to canines in the placebo group with score reductions of approximately 50 percent versus 15 percent, respectively. Furthermore, while pedometer measurements showed no significant changes in the mobility of canines in the placebo group, the canines treated with Alpha-GEE showed an approximately 30 percent increase in physical activity during the two-week trial period. No significant differences were observed in prostaglandin E₂ (“PGE₂”) plasma levels during the trial period in either treatment group; however serum amyloid A (“SAA”) levels were lower in canines in the Alpha-GEE treatment group compared to placebo at the end of the study. Together these findings provide clinical evidence of the effectiveness of treatments with Alpha-GEE in reducing the pain and restricted mobility of canines with OA.

Study Design

The double-blind study was performed on a total of 30 adult canines of various breeds in five different private practice clinics. Owner consent was obtained prior to participation in the study. Each clinic was responsible for enrolling 6 canines into the study. Inclusion criteria for the study consisted of clinical assessment and radiograph confirmation of OA in at least one joint and a score of 22 or greater on the Helsinki chronic pain index (“HCPI”). Use of NSAIDs or other dietary supplements for OA were allowed, provided the current treatment regimens had not been altered for a period of at least three months. A randomized block design was used with canines assigned in a one to one ratio into either placebo (36 mg/kg/day maltose-dextran; Vireo Resources, Plattsmouth, NE) or Alpha-GEE (36 mg/kg/day; Vireo Resources, Plattsmouth, NE) treatment group. The block size was six canines, corresponding to the total number of canines enrolled from each clinic. Group assignments for each canine were blinded to both the owners and attending veterinarian until all the data was collected and reported. Both Alpha-GEE and placebo were provided in 400 mg capsules and owners were instructed on the proper method for daily oral administration of capsules to their canines and provided with the appropriate number of capsules for the duration of the 2-week study. Blood samples were taken at both the start and conclusion of the two-week trial period to monitor for changes in blood chemistry as well as potential changes in inflammatory markers as described below. Owners completed the HCPI prior to starting the study, one-week after starting the study, and a final time at the conclusion of the study at two-weeks.

Canines participating in the study were also fitted with pedometers (Draco Tech International, Taiwan) to quantitatively track changes in daily activity during the course of the study. Use of pedometers to quantitatively assess activity has been demonstrated previously. The pedometers were fitted onto the collars at the clinic, and owners were instructed on care and maintenance of the pedometers and provided a log book to record the daily pedometer readings. Pedometer readings were recorded on a daily basis starting one week prior to the study and continuing throughout the two-week trial period. The daily pedometer readings recorded throughout an entire week (7-day period) were used to determine the average daily activity during the baseline period (one week prior to the start of the study) and the first and second weeks of the trial. Averaging of the daily pedometer readings over a 7-day period has been shown previously to provide the best reductions in intra and inter subject variability. Treatment-dependent changes in the activity of the canines were assessed by examining the changes in average daily pedometer readings from the first and second week periods to the average daily pedometer readings from the baseline period obtained prior to the start of the study.

Measurement of Inflammatory Markers in Plasma

In addition to the standard blood chemistry profile, blood samples taken before and at the conclusion of the two-week trial period were analyzed for PGE₂ and SAA. Blood samples were collected in heparin tubes for PGE₂ and in serum collection tubes for SAA. Both plasma and serum samples were centrifuged at 2000× g for 10 minutes and the plasma and serum supernatants removed and frozen at 20° C. until analyzed for PGE₂ and SAA using enzyme-linked immunosorbent assays (“EIA”). Of the 30 canines enrolled, 8 were excluded from the blood analysis portion of the study due to sampling/storage issues resulting in a lack of a pre- or post-trial sample. As PGE₂ is rapidly metabolized in plasma, measurement of PGE₂ metabolites is the most reliable method for assessing plasma levels of PGE₂. Plasma samples were analyzed for PGE₂ using the bicycle PGE₂ competitive EIA kit purchased from Cayman Chemical (Ann Arbor, Mich.). The assay converts PGE₂ metabolites into a stable derivative that is measured using EIA. Samples (100 μl) were analyzed in triplicate and PGE₂ concentrations determined by use of standard curve. For SAA measurements, a solid phase sandwich EIA kit (Tridelta Development Ltd, Maytooth, Co Kildare, Ireland) was used as described previously.

Statistics

Statistical evaluations of pain (HCPI), mobility (pedometer readings), and inflammatory markers were performed using ANOVA and Student Newman Keuls post-hoc comparison of means.

Results

A total of 30 canines of various breeds were enrolled in the study. A total of 28 canines completed the study with one canine in the placebo group discontinuing due to gastrointestinal irritation and one canine in the Alpha-GEE group removed due to a brain tumor discovered after partial completion of the trial. As shown in Table 1 below, information concerning the general demographics of the two groups is summarized. The age and sex of the canines were comparable in both treatment groups. A total of 4 canines in the placebo group were maintained on NSAIDs and/or dietary supplements for OA, compared to 3 canines in the Alpha-GEE treatment group. The average number of joints with radiograph confirmation of OA in the placebo and Alpha-GEE group was 2 and 3, respectively.

TABLE 1 Characteristics of OA Canines Enrolled In Trial Current Joints Age (yrs) Weight (lbs) Meds with OA Mean ± # of # of Mean ± # Mean ± SD Range Males Females SD range canines SD Placebo 12 ± 3 7-15 8 7 58 ± 21 17-90  4/14 2 ± 1 Alpha-GEE 11 ± 3 5-14 7 8 60 ± 29 13-100 3/14 3 ± 1

Owner assessment of pain and mobility in canines participating in the trial were based on the HCPI. The HCPI is a method for appraisal of pain and mobility in canines. The assessment is based on owner responses to eleven questions with a numerical answer between 0-4. Scoring on the HCPI ranges from 0 to 44, with higher numbers reflecting more pain and immobility present in the canine. Canines in both placebo and treatment group had similar initial pre-trial HCPI scores. After the first week of the trial, modest improvements in the HCPI score were observed in both the placebo and Alpha-GEE treatment groups. However, the reductions (approximately 10-15 percent in magnitude) in HCPI scores obtained in both the placebo and Alpha-GEE treatment groups after the first week resulted in HCPI scores that were not statistically different from each other. While no further improvements were observed after the second week of the trial in the canines receiving placebo, the HCPI scores were further reduced in the Alpha-GEE treatment group from the pre-trial values of 28 to post-trial values of 15. This represents an approximately 46 percent reduction from the original pre-trial values. The HCPI scores at the conclusion of the study in the Alpha-GEE treatment group were significantly different (p<0.001) from that of the placebo group. The magnitude of change in HCPI scores during the entire trial ranged from -1 to 9 (with mean+SD=3+4) for placebo compared to 2 to 20 (with mean +SD =13 +7) for Alpha-GEE treated canines.

The activity levels of the canines in the study were also assessed during the two-week trial. Pedometer readings from the canines in the placebo group did not change significantly over the trial period. In contrast, canines in the Alpha-GEE treatment group displayed significant increases in daily pedometer readings (i.e., mobility) at both the first (approximately 20 percent increase) and second (approximately 30% increase) week of the trial. The recorded changes in weekly pedometer readings in the Alpha-GEE treatment group were significantly different from that of the placebo group after both the first (p<0.05) and second (p<0.01) weeks of the trial.

The standard blood chemistry profiles of the canines enrolled in the study are shown in Table 2.

TABLE 2 Blood Chemistry Profile of OA Canines For Trial Period Placebo Alpha-GEE Pre- Post- Pre- Post- Normal Parameter Trial Trial Trial Trial Range ALT (U/L) Mean ± SD 63 ± 55 60 ± 52 89 ± 99 53 ± 37 10-118 U/L range 18-235 10-160 10-403 10-95  ALP (U/L) Mean ± SD 207 ± 167 243 ± 194 110 ± 104 103 ± 131 20-150 U/L range 31-584 53-654 24-368 25-382 Glucose Mean ± SD 101 ± 15  102 ± 19  102 ± 11  101 ± 11  80-110 mg/dL (mg/dL) range 91-114 91-115 75-125 87-116 Creatinine Mean ± SD 1.1 ± 0.4 1.1 ± 0.4 1.2 ± 0.7 1.5 ± 0.7 0.3-1.4 mg/dL (mg/dL) range 0.7-1.7  0.8-1.4  0.7-2.5  0.8-2.5  BUN Mean ± SD 18 ± 4  17 ± 4  24 ± 22 24 ± 19 7-25 mg/dL (mg/dL) range 12-29  8-27 8-66 8-65 Total Protein Mean ± SD 6.5 ± 0.7 6.7 ± 0.7 6.6 ± 0.4 6.5 ± 0.4 5.4-8.2 g/dL (g/dL)

Not surprisingly, given the age of the canines in the study, there were values out of the normal range observed in both placebo and Alpha-GEE treatment groups. Aside from total protein in which there were no canines above the normal expected range, there was at least one canine in each treatment group that had values in the blood chemistry profile that were above the normal range. However, it should be noted that compared to the pre-trial values, there were no significant changes in the post-trial blood chemistry profiles during the trial period observed for either placebo or Alpha-GEE treated canines. Thus indicating that during the course of the two-week trial there were no significant changes in the blood chemistry profiles for canines in either placebo or Alpha-GEE treatment group.

Examination of PGE₂ and SAA, two inflammatory markers, was performed both prior to (pre-trial) and immediately following (post-trial) the two-week treatment period. As shown in Table 3, there was no difference in the pre-trial and post-trial plasma levels for PGE₂ in either the placebo or Alpha-GEE treated canines.

TABLE 3 Plasma Concentrations of Inflammatory Markers in OA Canines for the Trial Period Pre-Trial Values Post-Trial Values Inflammatory Marker Placebo Alpha-GEE Placebo Alpha-GEE P Value PGE₂ Mean ± SD 250 ± 16  268 ± 11  275 ± 20  264 ± 10  (pg/ml) 95% CI 240-260  261-275  245-269  258-270 Serum Mean ± SD 760 ± 752 673 ± 869 1483 ± 1653 255 ± 221* 0.048 Amyloid A (ng/ml) 95% CI 368-1297 193-1297 555-2651 141-412 *p < 0.05 compared to placebo at same time point

A wide range of values was obtained for SAA in both placebo and Alpha-GEE treatment groups. While there were no significant differences in the pre-trial levels of SAA in the placebo and Alpha-GEE groups, SAA levels were significantly lower in the Alpha-GEE treatment group at the conclusion of the study. Specifically, SAA levels were reduced by at least 30% and by as much as 70% from values prior to treatment with Alpha-GEE.

Example 2 Effects of Alpha-GEE and Ibuprofen on the Release of PGE₂ in Brain Endothelial Cells

In this example, the effects of Alpha-GEE and Ibuprofen on the release of PGE₂ from brain endothelial cells were compared. The brain endothelial cells were first exposed to bacterial endotoxin. The effects of Alpha-GEE and Ibuprofen were then measured and the levels of release of PGE₂ were compared.

FIG. 1 demonstrates that the reduction in the release of PGE₂ from brain endothelial cells at an Alpha-GEE concentration of about 20 μM or more is about 50 percent or more. The reduction in the release of PGE₂ from brain endothelial cells at an Alpha-GEE concentration of about 1000 μM or more greater than about 50 percent. The reduction of PGE₂ release observed with Alpha-GEE is similar in magnitude to the reduction of PGE₂ release observed with ibuprofen treatment,

Example 3 Effects of Alpha-GEE and Ibuprofen on Inhibition of Cyclooxygenase (“COX”) Activity

The effects of Alpha-GEE and Ibuprofen on the inhibition of cyclooxygenase-1 (“COX1”) and cyclooxygenase-2 (“COX2”) activity were also compared. As shown in FIG. 2, NSAIDs, such as ibuprofen, chemically bind to cyclooxygenase and inhibit prostaglandin production. Specifically, the NSAID, Ibuprofen, produced a concentration dependent inhibition of the COX enzymes when used at concentrations of 0.1-100 μM. For example, greater than about 60 percent of COX-1 and COX-2 activity is inhibited with Ibuprofen. In contrast, Alpha-GEE did not show a concentration dependency on the inhibition of COX enzymes. In other words, Alpha-GEE did not show a mechanistic inhibition of the COX enzymes. This suggests that the anti-inflammatory pathway for Alpha-GEE is different from that of NSAIDs commonly used to treat conditions such as OA.

Example 4 Effects of Alpha-GEE and Other Anti-Inflammatory Compounds on TNFa and PGE2 Release in Canine Chondrocytes

The following example compares the effects of Alpha-GEE and other anti-inflammatory compounds on PGE₂ release, as well as TNFa release, in cultured canine chondrocytes.

The study involved the use of cultured canine chondrocytes (i.e., cells within the joint that are activated during OA). The canine chondrocytes were subjected to an inflammatory challenge in the form of cytokine Interleukin 1 beta (“IL1b”). The canine chondrocytes were then treated with various anti-inflammatory compounds including Alpha-GEE; glucosamine; a TNFa receptor antagonist; and a NSAID (Rimadyl). Alpha-GEE was administered in concentrations ranging from 10 uM to 1000 uM. The resulting effects of the various treatments on both PGE₂ release and TNFa release were examined.

As shown in FIG. 3, the results from the study showed a time-dependent reduction in PGE₂ release from chondrocytes following treatment with Alpha-GEE. Alpha-GEE, glucosamine, and Rimadyl were used in a concentration of 100 μM, while the TNFa inhibitor was used in a concentration of 1 μM. Based on all of the treatments examined (i.e., Alpha-GEE; glucosamine; NSAID (Rimadyl); and TNFa receptor antagonist), Alpha-GEE produced the most dramatic decrease in PGE₂ at the early 4-hour time point. The Alpha-GEE treatment showed an approximately 60 percent reduction in PGE₂ at 4 hours. The reduction in PGE₂ release at the early 4 hour time point was greater than that observed with the NSAID, Rimadyl, glucosamine, or TNFa receptor blocker. The maximal effect of Alpha-GEE on PGE₂ release from chondrocytes was observed within 8 hours, where a 75% reduction in PGE₂ release was observed. Maximal effects were observed at concentrations of Alpha-GEE of 100 uM. The effects of Alpha-GEE on PGE₂ release were consistently greater in magnitude than glucosamine and depending on the time examined, comparable to the NSAID or TNFa receptor antagonist.

Accordingly, the data in FIGS. 1, 2, and 3 collectively demonstrate that upon administration of Alpha-GEE, prostaglandin production and release is reduced without direct inhibition of cyclooxygenase enzymes, which is the mechanism of action of NSAIDs, such as ibuprofen and Rimadyl.

A similar time dependent decrease in TNFa release was also observed in chondrocytes treated with Alpha-GEE, as shown in FIG. 4. Alpha-GEE showed significant and sustained reductions in TNFa release from chondrocytes. The Alpha-GEE treatment demonstrated about 40 percent to about 60 percent reductions in TNFa release depending on the time point examined. This is in contrast to glucosamine that had no significant effect on TNF release and Rimadyl, which produced a significant increase in TNF release in chondrocytes.

Although the present invention has been described with reference to particular embodiments, it will be understood to those skilled in the art that the invention is capable of a variety of alternative embodiments within the spirit of the appended claims. For example, the method of the present invention is also contemplated for use as a preventative treatment to attenuate the effects of pain and inflammation associated with osteoarthritis. 

What is claimed is:
 1. A method for treating an inflammatory disease comprising: administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate.
 2. The method of claim 1, wherein the anti-inflammatory agent is administered to the patient in an oral dosage or as a topical application.
 3. The method of claim 2, wherein the topical application is administered in an amount of about 0.5 mL to about 5 mL.
 4. The method of claim 1, wherein the patient is a human, a canine, or an animal.
 5. The method of claim 1, wherein the inflammatory disease is osteoarthritis.
 6. The method of claim 2, wherein the oral dosage is administered in an amount of about 400 mg to about 2400 mg.
 7. A method for reducing acute blood levels of pro-inflammatory marker, serum amyloid A, comprising: administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate.
 8. The method of claim 7, wherein the acute blood levels of serum amyloid A are reduced by about 30 percent to about 70 percent when compared to levels of serum amyloid A prior to administration of the anti-inflammatory agent.
 9. The method of claim 7, wherein the anti-inflammatory agent is administered to the patient in an oral dosage of about 400 mg to about 2400 mg.
 10. A method for reducing production and release of pro-inflammatory prostanoids in cells comprising: administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate.
 11. The method of claim 10, wherein the pro-inflammatory prostanoids are reduced by about 50 percent or more when compared to an amount of pro-inflammatory prostanoids prior to administration of the anti-inflammatory agent.
 12. The method of claim 11, wherein the pro-inflammatory prostanoids are reduced by about 70 percent or more when compared to an amount of pro-inflammatory prostanoids prior to administration of the anti-inflammatory agent.
 13. The method of claim 10, wherein the pro-inflammatory prostanoids comprise prostaglandin E₂.
 14. A method for reducing levels of serum amyloid A, pro-inflammatory prostanoids, and tumor necrosis factor alpha in a patient, comprising: administering an effective amount of ethyl (α-guanido-methyl) ethanoate to the patient.
 15. The method of claim 14, wherein the levels of serum amyloid A are reduced by about 40 percent to about 60 percent when compared to levels of serum amyloid A prior to administration of the ethyl (α-guanido-methyl) ethanoate.
 16. The method of claim 14, wherein the levels of pro-inflammatory prostanoids are reduced by about 50 percent or more when compared to levels of pro-inflammatory prostanoids prior to administration of the ethyl (α-guanido-methyl) ethanoate.
 17. The method of claim 14, wherein the levels of tumor necrosis factor alpha are reduced by about 40 percent to about 60 percent when compared to levels of tumor necrosis factor alpha prior to administration of the ethyl (α-guanido-methyl) ethanoate.
 18. The method of claim 14, wherein the effective amount of ethyl (α-guanido-methyl) ethanoate is an oral dosage of about 400 mg to about 2400 mg.
 19. The method of claim 14, wherein the step of administering further comprises administering at least one other compound in conjunction with the ethyl (α-guanido-methyl) ethanoate.
 20. The method of claim 19, wherein the at least one other compound is selected from the group consisting of homeopathic compounds, co-medications, nutraceuticals, plant extracts, herbal preparations, and cosmetic agents. 